The following amendment has been made to the 'Notice of Results' announcement released on 20 November 2025 at 07.00am under RNS No 2684I.
The results period has been corrected to the six months ended 30 September 2025.
All other details remain unchanged.
The full amended text is shown below.
20 November 2025
ECO Animal Health Group plc
("ECO" or the "Company")
Notice of Results
Analyst Briefing and Investor Presentation
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, will announce its unaudited interim results for the six months ended 30 September 2025 on 1 December 2025.
David Hallas, CEO, and Christopher Wilks, CFO, will host an in-person analyst briefing at 09:00 GMT on 1 December 2025. There will be a dial-in option for those unable to attend in person. For further information about the analyst presentation, please contact [email protected].
In addition, David Hallas and Christopher Wilks will conduct a live online presentation and Q&A at 14:00 GMT on 2 December 2025. This event is open to all existing and potential shareholders and registration is free. To register for the event, please click here.
-Ends-
Contacts
|
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)
|
|
| ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson
|
020 3709 5700
|
| Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies Sam Butcher
|
020 7496 3000 |
| Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden
|
020 3100 2000
|
| Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
| |
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com